Prelingual sensorineural hearing loss is a sensorial deficit either congenital, either acquired due to perinatal period associated risk factors. Among these, congenital infection with cytomegalic virus (CMV) and ototoxic-induced deafness have a high incidence. CMV is the most common congenital viral infection, with birth prevalence of 0.48 to 1.3 percent in recent decades. The congenital infection may be asymptomatic or symptomatic; the symptomatic disease can be severe and life-threatening. Both asymptomatic and symptomatic newborns are at risk of developing long-term neurodevelopmental morbidity, particularly deafness. Recently, the neurological complications caused by congenital CMV infection in affected infants have been successfully treated with antiviral agents, but the early diagnosis of congenital infection is vital for this treatment to be effective. To identify the primary CMV infection, maternal blood tests for CMV-specific immunoglobulin (Ig) M antibodies (CMV IgM) are widely used. However, CMV IgM tests can remain positive for years after primary infection, so a positive result for CMV IgM does not always indicate primary infection during pregnancy. A CMV IgG avidity test is also used for identifying a recent infection. The screening for congenital CMV infection is an issue for debate for the moment, but its severe consequences, similar to those of Zika infection, should rise more concern and research studies regarding neonatal screening. Ototoxic-induced deafness is frequently met because aminoglycoside antibiotics (gentamycin, vancomycin) are the first-line antibiotics in neonatal sepsis - they are cheap and with a broad spectrum. The correct posology when using these antibiotics has a significant influence in reducing the risk of ototoxic-induced deafness. [ABSTRACT FROM AUTHOR]